CERS:NSD-Cerus Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.03

Change

+0.03 (+0.50)%

Market Cap

USD 0.98B

Volume

1.81M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-1.40 (-0.83%)

USD66.76B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-3.78 (-1.72%)

USD56.88B 21.36 15.53
REGN Regeneron Pharmaceuticals, Inc

-16.05 (-3.17%)

USD54.26B 16.60 12.83
BNTX BioNTech SE

+7.15 (+4.42%)

USD37.72B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

-0.79 (-0.47%)

USD37.13B 61.79 35.79
BGNE BeiGene, Ltd

+9.06 (+3.00%)

USD28.73B N/A N/A
SGEN Seagen Inc

-3.84 (-2.60%)

USD26.74B 43.77 35.78
RPRX Royalty Pharma plc

+0.43 (+1.01%)

USD25.97B 22.60 15.19
GMAB Genmab A/S

+0.28 (+0.77%)

USD23.74B 26.59 3.37
CVAC CureVac N.V

+1.16 (+1.03%)

USD20.99B N/A N/A

ETFs Containing CERS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.86% 33% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.86% 33% F 16% F
Trailing 12 Months  
Capital Gain 12.40% 44% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.40% 44% F 21% F
Trailing 5 Years  
Capital Gain -9.32% 50% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.32% 50% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 21.32% 56% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.32% 55% F 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 68.48% 45% F 23% F
Risk Adjusted Return 31.13% 57% F 53% F
Market Capitalization 0.98B 71% C- 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.59 22% F 18% F
Price / Cash Flow Ratio -23.96 82% B- 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -73.39% 40% F 16% F
Return on Invested Capital -46.27% 53% F 18% F
Return on Assets -19.98% 64% D 20% F
Debt to Equity Ratio 38.14% 30% F 47% F
Technical Ratios  
Short Ratio 5.23 37% F 18% F
Short Percent 5.56% 57% F 36% F
Beta 1.33 53% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.